Terry Brady

Elephas

Elephas is developing a technology platform to assess how live tumor cells respond to cancer therapies. We are harnessing the latest advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence to revolutionize cancer treatment. Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite advances in precision medicine and a significant increase in the number of available therapies, many cancer patients still derive no benefit from their treatment. Immunotherapy is an emerging type of treatment that can greatly benefit patients when it is successful. Unfortunately, today only 1 in 3 patients receiving therapy respond and only 1 in 5 receiving immunotherapy respond. We maintain the native 3-dimensional cellular architecture of a patient's tumor and enable ex-vivo real-time profiling of live tumor samples. The platform is being developed for use with immunotherapy agents alone and in combination with traditional chemotherapy and targeted therapies. THE ELEPHAS MISSION To develop innovative cancer diagnostic products and services that enable accurate prediction of clinical treatment outcomes and accelerate drug development